13 Results for "

acetylated histone H3

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "acetylated histone H3" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-16531
CAS No.: 1311423-89-8
Research Areas:  

Neurological Disease Cancer

YF-2 is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16531A
CAS No.: 1312005-62-1
Research Areas:  

Neurological Disease Cancer

YF-2 hydrochloride is a highly selective, blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, with EC50s of 2.75 μM, 29.04 μM and 49.31 μM for CBP, PCAF, and GCN5, respectively, shows no effect on HDAC. Anti-cancer and anti-Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-145550
CAS No.: 1610044-98-8
Purity:  98.97%
Synonyms: BI894999
Research Areas:  

Cancer

Amredobresib (BI894999) is an orally active BET inhibitor. Amredobresib inhibits the binding of BRD4-BD1 and BRD4-BD2 bromodomains to acetylated histones with IC50 values of 5 nM and 41 nM, respectively. Amredobresib exhibits anticancer activity against acute myeloid leukemia (AML) and NUT cancer .
loading...
    loading...
Cat. No.: HY-171140
Research Areas:  

Cancer

PROTAC HDAC6 degrader 3 is a selective HDAC6 PROTAC degrader with an IC50 of 0.686 μM and shows high selectivity for HDAC6 over HDAC1-4. PROTAC HDAC6 degrader 3 recruits cereblon (CRBN) to trigger HDAC6 ubiquitination and subsequent proteasomal degradation. PROTAC HDAC6 degrader 3 selectively elevates acetylated α-tubulin levels in cancer cells, and does not induce histone H3 hyperacetylation or obvious loss of cell viability. PROTAC HDAC6 degrader 3 is applicable for research on multiple myeloma .
loading...
    loading...
Cat. No.: HY-149669
CAS No.: 3053430-96-6
Purity:  99.29%
Research Areas:  

Cancer

PH14 is a PI3Kα/HDAC3 inhibitor, with an IC50 value of 20.3 nM against PI3Kα and 24.5 nM against HDAC3. PH14 blocks the phosphorylation of AKT, inhibits the PI3K/AKT signaling pathway, increases the level of acetylated histone H3, promotes apoptosis, and exerts antiproliferative activity against tumor cells. PH14 can be used in the research of mantle cell lymphoma, myeloma, acute promyelocytic leukemia, and breast cancer .
loading...
    loading...
Cat. No.: HY-171139
Research Areas:  

Cancer

PROTAC HDAC6 degrader 2 is a non‑hydroxamate selective HDAC6 PROTAC degrader with an IC50 of 0.643 μM and shows high selectivity for HDAC6 over HDAC1-4. PROTAC HDAC6 degrader 2 recruits VHL E3 ubiquitin ligase to trigger HDAC6 ubiquitination and subsequent proteasomal degradation. PROTAC HDAC6 degrader 2 selectively elevates acetylated α-tubulin levels in cancer cells, and does not induce histone H3 hyperacetylation or obvious loss of cell viability. PROTAC HDAC6 degrader 2 is applicable for research on multiple myeloma .
loading...
    loading...
Cat. No.: HY-178110
CAS No.: 3028442-70-5
Research Areas:  

Cancer

HDAC6-IN-65 is a selective HDAC6 inhibitor (IC50 = 0.9 nM) and also exhibits a certain suppressive effect on HDAC3 (IC50 = 39.4 nM). HDAC6-IN-65 can induce the accumulation of α-tubulin (ac-tubulin) and acetylated histone H3 (ac-histone H3, a class I HDAC inhibition marker) in Neuro-2a cells. HDAC6-IN-65 can be used for the study of melanoma .
loading...
    loading...
Cat. No.: HY-155329
CAS No.: 3032392-65-4
Target:  

HDAC

Research Areas:  

Inflammation/Immunology

GK718 is a HDAC1/3 inhibitor (IC50: 259 and 139 nM respectively). GK718 increased acetylated histone H3 level in cells. GK718 inhibits Bleomycin (HY-108345) induced pulmonary fibrosis in mice .
loading...
    loading...
Cat. No.: HY-175671
Research Areas:  

Neurological Disease

LSD1/HDAC-IN-3 is a inhibitor targeting class I HDAC and LSD1 enzymes. LSD1/HDAC-IN-3 inhibits HDAC1, HDAC2, HDAC3, and LSD1 with IC50 values of 1702 nM, 842 nM, 358 nM, and 1074 nM, respectively. LSD1/HDAC-IN-3 exhibits antioxidant effects in H2O2-stressed ARPE-19 and 661W retinal cells, increasing levels of acetylated and methylated histone H3. LSD1/HDAC-IN-3 enhances photoreceptor survival in the rd10 mouse model of retinitis pigmentosa. LSD1/HDAC-IN-3 can be used for the study of inherited retinal diseases such as retinitis pigmentosa (RP) .
loading...
    loading...
Cat. No.: HY-156091
CAS No.: 3007565-26-3
Target:  

PI3K HDAC

Research Areas:  

Cancer

PI3Kα/HDAC6-IN-1 (compound 21j) is a dual PI3Kα/HDAC6 inhibitor with IC50 of 2.9 and 26 nM, respectively. PI3Kα/HDAC6-IN-1 also inhibits AKT(Ser473) phosphorylation and induces the accumulation of acetylated α-tubulin without affecting acetylated histones H3 and H4. PI3Kα/HDAC6-IN-1 efficiently inhibits L-363 cell line (IC50=0.17 μM) and has good anti-cancer activity .
loading...
    loading...
Cat. No.: HY-121009
CAS No.: 748777-47-1
Research Areas:  

Cancer

CCT077791 is a PCAF (IC50: 7.3 μM (FlashPlate); 2.2 μM (Filter assay)) and p300 histone acetyltransferase inhibitor. CCT077791 reduces total acetylation of histones H3 and H4, levels of specific acetylated lysine marks, and acetylation of α-tubulin. CCT077791 can be used in the research of colorectal cancer .
loading...
    loading...
Cat. No.: HY-182720
CAS No.: 2379645-28-8
Research Areas:  

Cancer

FT108 is a selective HDAC6 inhibitor with an IC50 of 0.026 μM. FT108 exhibits only modest in vitro activity against HDAC3 and HDAC8 with IC50 values of 6.68 and 4.07 μM. FT108 increases acetylation of tubulin and has little to no effect on acetylated histone H3 levels. FT108 lacks activity against myeloproliferative neoplasm cell lines, and does not suppress JAK2 phosphorylation or its downstream targets pSTAT3 and pSTAT5 .
loading...
    loading...
Cat. No.: HY-184415
Syk/HDAC6-IN-1 is a dual SYK/HDAC6 selective inhibitor with IC50 values of 0.19 nM (SYK) and 0.66 nM (HDAC6). Syk/HDAC6-IN-1 downregulates p-SYK to block downstream AKT/FOXO1 signaling, elevates acetylated histone H3 and α-tubulin via HDAC suppression, represses SREBF1 -mediated lipid biosynthetic pathways, triggers G0/G1 cell cycle arrest and robust mitochondrial-dependent caspase-3-mediated apoptosis in leukemia cells. Syk/HDAC6-IN-1 can be used for the research of FLT3-mutant acute myeloid leukemia .
loading...
    loading...
  • 1